Upadacitinib - AbbVie

Drug Profile

Upadacitinib - AbbVie

Alternative Names: ABT-494; Upadacitinib tartrate

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Antirheumatics; Fluorocarbons; Imidazoles; Pyrazines; Pyrroles; Pyrrolidines
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase II Ankylosing spondylitis; Atopic dermatitis

Most Recent Events

  • 24 Nov 2017 AbbVie plans a phase III trial for Crohn's disease (In adults, In the elderly, Treatment-experienced) in USA and Austria (NCT03345823)
  • 20 Nov 2017 AbbVie initiates enrolment in a phase III trial for Crohn's disease (In the elderly, Treatment experienced, In adults) in USA (NCT03345836)
  • 19 Nov 2017 Phase-III clinical trials in Crohn's disease (In the elderly, Treatment-experienced, In adults) in USA (PO) (NCT03345849)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top